Fluvoxamine Quantitative, Serum or Plasma
Also known as: FLUVOXAM
Use
The Fluvoxamine Quantitative, Serum or Plasma test is essential for therapeutic drug monitoring, ensuring optimal dosing of fluvoxamine and preventing potential side effects or subtherapeutic dosing. It is particularly valuable in patient management for those on a daily regimen of 150 to 300 mg/day, where steady-state plasma levels are expected to range between 78-920 ng/mL.
Special Instructions
This test requires specific serum or plasma handling. Blood should be collected in a plain red, lavender (K2EDTA), or pink (K3EDTA) tube, and separated from cells as soon as possible or within 2 hours of collection. Transfer to an ARUP standard transport tube is necessary for accurate testing.
Limitations
The test is performed by NMS Labs and has not been cleared or approved by the US FDA. Analytical limitations include the reporting limit set at 10 ng/mL, and test results may be subject to review digitally by NMS staff remotely, adhering to CLIA regulations. The test must be run separately at NMS Labs with no capacity for combined testing at ARUP.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
Result Turnaround Time
8-11 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.4 mL
Container
ARUP standard transport tube
Collection Instructions
Separate serum or plasma from cells ASAP or within 2 hours of collection.
Causes for Rejection
Separator tubes
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 month |
| Frozen | 3 months |